Back to top

IRSJD researchers collaborate in the identification of two subtypes of retinoblastoma

The study in which the Institut de Recerca Sant Joan de Déu is collaborating will help to improve the diagnosis and treatment of this childhood cancer.

Published in:
19 November 2021
Dr. Jaume Català Mora examines a patient with retinoblastoma.
Dr. Jaume Català Mora, one of the study researchers, examines a patient with retinoblastoma.
https://www.sjdhospitalbarcelona.org/sites/default/files/u1/Sala_premsa/Noticias/2021/prova-retcam-retinoblastoma-hospital-sant-joan-deu-barcelona.jpg

A research team at the Institut de Recerca Sant Joan de Déu has collaborated in an international study that shows that there are two molecular retinoblastoma subtypes with different genomic, clinical and pathological characteristics. The study has been published in the journal Nature Communications.

This new information points to new biological and clinical insights to better understand retinoblastoma and will help to improve diagnosis, to choose more targeted treatments and to design new ones.

The research team has analysed more than 100 retinoblastomas and has identified two subtypes with different genomic, clinical and pathological characteristics, such as age at diagnosis, inheritance or the way the tumour grows.

Retinoblastoma subtypes 1 have fewer genetic alterations in the retinal cells than retinoblastoma subtype 2. However, retinoblastoma subtypes 2 are more aggressive, have a higher risk of metastasis and are more resistant to certain therapies

MORE INFORMATION IN IRSJD WEBSITE 

Hospital Sant Joan de Déu https://www.sjdhospitalbarcelona.org/sites/default/themes/hsjd/logo.svg
IRSJD researchers collaborate in the identification of two subtypes of retinoblastoma